{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:17:59Z","timestamp":1791152279886,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,15]]},"DOI":"10.1097\/qad.0b013e328352224d","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T09:28:29Z","timestamp":1329211709000},"page":"939-949","source":"Crossref","is-referenced-by-count":45,"title":["Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV\u2013hepatitis B virus-infected patients"],"prefix":"10.1097","volume":"26","author":[{"given":"Sarah","family":"Maylin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Lavocat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Gozlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lascoux-Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Miailhes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210130","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/QAI.0b013e31817efb54","article-title":"Changes in causes of death among adults infected by HIV between 2000 and 2005: the Mortalite 2000 and 2005 surveys (ANRS EN19 and Mortavic).","volume":"48","author":"Lewden","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R2-5-20210130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1473-3099(07)70264-5","article-title":"Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.","volume":"8","author":"Papatheodoridis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R3-5-20210130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B.","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"R4-5-20210130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"R5-5-20210130","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2010.04.041","article-title":"Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.","volume":"53","author":"Piroth","year":"2010","journal-title":"J Hepatol"},{"key":"R6-5-20210130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"R7-5-20210130","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"R9-5-20210130","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"R10-5-20210130","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"R11-5-20210130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/135965350801300402","article-title":"A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.","volume":"13","author":"Wiegand","year":"2008","journal-title":"Antivir Ther"},{"key":"R12-5-20210130","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"R13-5-20210130","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.22065","article-title":"HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.","volume":"47","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"R14-5-20210130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2893.2005.00602.x","article-title":"Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B.","volume":"12","author":"Park","year":"2005","journal-title":"J Viral Hepat"},{"key":"R15-5-20210130","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.3748\/wjg.v12.i41.6693","article-title":"Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.","volume":"12","author":"Shin","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R16-5-20210130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1872-034X.2009.00592.x","article-title":"Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B.","volume":"40","author":"Tangkijvanich","year":"2010","journal-title":"Hepatol Res"},{"key":"R17-5-20210130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3851\/IMP1723","article-title":"Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.","volume":"16","author":"Thibault","year":"2011","journal-title":"Antivir Ther"},{"key":"R18-5-20210130","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/01.aids.0000171404.07995.5c","article-title":"Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.","volume":"19","author":"Lacombe","year":"2005","journal-title":"AIDS"},{"key":"R19-5-20210130","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1128\/JCM.00344-10","article-title":"Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome.","volume":"48","author":"Gauthier","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R20-5-20210130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jviromet.2003.10.002","article-title":"Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay.","volume":"115","author":"Deguchi","year":"2004","journal-title":"J Virol Methods"},{"key":"R21-5-20210130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker.","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"R22-5-20210130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350701200107","article-title":"Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.","volume":"12","author":"Manesis","year":"2007","journal-title":"Antivir Ther"},{"key":"R23-5-20210130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS"},{"key":"R24-5-20210130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAD.0b013e328340fde2","article-title":"Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.","volume":"25","author":"Martin-Carbonero","year":"2011","journal-title":"AIDS"},{"key":"R25-5-20210130","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1086\/520752","article-title":"Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.","volume":"45","author":"Miailhes","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R27-5-20210130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/jac\/dkp479","article-title":"Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.","volume":"65","author":"Soriano","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R28-5-20210130","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3851\/IMP1458","article-title":"Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.","volume":"14","author":"Moucari","year":"2009","journal-title":"Antivir Ther"},{"key":"R29-5-20210130","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/gut.2004.060327","article-title":"Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.","volume":"54","author":"Erhardt","year":"2005","journal-title":"Gut"},{"key":"R30-5-20210130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","article-title":"Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.","volume":"101","author":"Flink","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R31-5-20210130","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1053\/gast.2002.37041","article-title":"Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.","volume":"123","author":"Sanchez-Tapias","year":"2002","journal-title":"Gastroenterology"},{"key":"R32-5-20210130","first-page":"40","article-title":"Treatment of HIVHBV coinfection: clinical and virologic issues.","volume":"9","author":"Thio","year":"2007","journal-title":"AIDS Rev"},{"key":"R33-5-20210130","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/jmv.20935","article-title":"Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.","volume":"79","author":"Hou","year":"2007","journal-title":"J Med Virol"},{"key":"R34-5-20210130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jmv.20262","article-title":"Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.","volume":"75","author":"Kohmoto","year":"2005","journal-title":"J Med Virol"},{"key":"R38-5-20210130","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1073\/pnas.0403925101","article-title":"Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration.","volume":"101","author":"Bill","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R39-5-20210130","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.3748\/wjg.v11.i41.6416","article-title":"Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B.","volume":"11","author":"Kimbi","year":"2005","journal-title":"World J Gastroenterol"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-201205150-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T17:35:31Z","timestamp":1686764131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201205150-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,15]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328352224d","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5,15]]}}}